Shetty H G, Fennerty A G, Routledge P A
Department of Pharmacology and Therapeutics, University of Wales College of Medicine, Health Park, Cardiff, Wales.
Clin Pharmacokinet. 1989 Apr;16(4):238-53. doi: 10.2165/00003088-198916040-00003.
Aspects of the pharmacokinetics of warfarin that are clinically relevant are reviewed here. Since warfarin is normally completely absorbed, resistance to treatment due to impaired absorption is unusual, even in severe short bowel syndrome. Warfarin is highly albumin-bound; thus, hypoalbuminaemic states result in an increased free fraction of the drug and a decreased half-life but, as might be expected, there is no evidence of altered response at steady-state. Warfarin is completely metabolised by the liver to hydroxy-warfarins and warfarin alcohols, and although the latter have some biological activity they do not contribute significantly to the drug effect. No information is available concerning the metabolism of warfarin in chronic liver disease, but there is evidence of increased sensitivity due to impaired vitamin K-dependent clotting factor synthesis. Impaired renal function does not appear to alter the effect of warfarin. Lowered response to the drug may be secondary to poor compliance, kinetic resistance or pharmacodynamic resistance. These factors can be identified using algorithms based on population values for plasma warfarin concentrations and clearances at steady-state. The pharmacokinetics and pharmacodynamics of warfarin indicate that several days' overlap with heparin on initiation of warfarin, and gradual (rather than sudden) discontinuation of warfarin, might theoretically be necessary. However, those studies which have been performed have indicated that a long overlap and gradual discontinuation are not associated with greater safety or efficacy of the drug. Because of the long elimination half-life of warfarin and the short elimination half-life of vitamin K, many days' treatment with phytomenadione may be required after warfarin overdose. The elimination half-life and therefore the duration of therapy may be reduced by regular oral cholestyramine, although the means by which the latter enhances warfarin elimination is still unknown.
本文综述了华法林临床相关的药代动力学方面。由于华法林通常完全吸收,即使在严重短肠综合征中,因吸收受损导致治疗抵抗的情况也不常见。华法林与白蛋白高度结合;因此,低白蛋白血症状态会导致药物的游离部分增加和半衰期缩短,但正如预期的那样,没有证据表明稳态时反应会改变。华法林在肝脏中完全代谢为羟基华法林和华法林醇,尽管后者有一些生物活性,但它们对药物作用的贡献不大。目前尚无关于华法林在慢性肝病中代谢的信息,但有证据表明由于维生素K依赖性凝血因子合成受损,敏感性增加。肾功能受损似乎不会改变华法林的作用。对药物反应降低可能继发于依从性差、动力学抵抗或药效学抵抗。这些因素可以使用基于稳态时血浆华法林浓度和清除率的群体值的算法来识别。华法林的药代动力学和药效学表明,在开始使用华法林时与肝素重叠几天,以及逐渐(而非突然)停用华法林,从理论上讲可能是必要的。然而,已进行的那些研究表明,长时间重叠和逐渐停用与药物的更高安全性或疗效无关。由于华法林的消除半衰期长而维生素K的消除半衰期短,华法林过量后可能需要用植物甲萘醌治疗数天。定期口服考来烯胺可能会缩短消除半衰期,从而缩短治疗持续时间,尽管后者增强华法林消除的机制仍不清楚。